uniQure N.V - Asset Resilience Ratio
uniQure N.V (UQ1) has an Asset Resilience Ratio of 10.94% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read uniQure N.V balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how uniQure N.V's Asset Resilience Ratio has changed over time. See uniQure N.V book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down uniQure N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see uniQure N.V market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €97.19 Million | 10.94% |
| Total Liquid Assets | €97.19 Million | 10.94% |
Asset Resilience Insights
- Moderate Liquidity: uniQure N.V has 10.94% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
uniQure N.V Industry Peers by Asset Resilience Ratio
Compare uniQure N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for uniQure N.V (2021–2024)
The table below shows the annual Asset Resilience Ratio data for uniQure N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 37.48% | €208.59 Million ≈ $243.86 Million |
€556.54 Million ≈ $650.65 Million |
-7.79pp |
| 2023-12-31 | 45.27% | €376.53 Million ≈ $440.21 Million |
€831.69 Million ≈ $972.33 Million |
+27.57pp |
| 2022-12-31 | 17.71% | €124.83 Million ≈ $145.94 Million |
€704.96 Million ≈ $824.18 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€809.18 Million ≈ $946.02 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more